Completed PHASE2 INTERVENTIONAL 3-arm NCT01069783

Study of A3309 in Patients With Dyslipidemia

A Phase IIa, Double-blind, Randomised, Placebo-controlled, Dose-finding Efficacy and Safety Study of A3309 in Patients With Dyslipidemia

Sponsor: Albireo

Conditions Dyslipidemia

Interventions A3309 Placebo

Updated 6 times since 2017 Last updated: Mar 6, 2024 Started: Feb 28, 2010 Primary completion: Sep 30, 2010 Completion: Sep 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Dyslipidemia, this trial is completed. The trial is conducted by Albireo and has accumulated 6 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2024 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Albireo

Data source: Ipsen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Linköping, Sweden